<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00139477</url>
  </required_header>
  <id_info>
    <org_study_id>04-032</org_study_id>
    <nct_id>NCT00139477</nct_id>
  </id_info>
  <brief_title>Study of Serum Markers for Cardiovascular Risk in Obese Youth and Impact of Lifestyle and Medication Intervention</brief_title>
  <official_title>Understanding the Effects of Therapeutic Intervention on Cardiovascular Risk Markers, Insulin Resistance, and Intra-Hepatic Fat Contents in Obese Children at High Risk for the Metabolic Syndrome.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nemours Children's Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Thrasher Research Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nemours Children's Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In Protocol #2, we will select 30 obese pubertal and 30 obese prepubertal subjects with an
      abnormal cytokine profile (i.e. fibrinogen and/or hsCRP concentration greater than or equal
      to 2 Standard Deviations (SD) above the mean established in our lab for lean controls in
      Protocol #1). They will be randomly assigned to either lifestyle intervention (diet/exercise)
      or diet/exercise plus metformin for 6 months. After the 6 month evaluation the subjects will
      cross over the treatment arms, i.e., those that were doing diet/exercise intervention only
      will add metformin, those that were doing the diet/exercise plus metformin will discontinue
      the metformin and continue with diet/exercise changes only. Intrahepatic fat contents will be
      measured as well.

      The investigators hypothesize that obese children in these age groups will have increased
      cardiovascular risk related to their obese state before reaching the currently defined
      criteria of metabolic syndrome.

      The investigators hypothesize that these cardiovascular risks can be reduced with lifestyle
      and drug interventions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2003</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Protocol #1: Serum Marker Levels Between Obese and Lean Children</measure>
    <time_frame>Screening Visit</time_frame>
    <description>This outcome measure is from Protocol #1 (a cross-sectional study); results are not posted.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in High-sensitivity C-reactive Protein (hsCRP) at 6 Months</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Value at 6 months minus value at baseline. HsCRP is an acute phase protein which is a sensitive marker for systemic inflammation. HsCRP concentrations were measured in our laboratory by immuno-nephelometry (Siemens Healthcare Diagnostics, Deerfield IL, USA), with an hsCRP lower sensitivity of 0.156 mg/L.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Fibrinogen at 6 Months</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Value at 6 months minus value at baseline. Fibrinogen is a hepatic-derived factor directly involved in clotting and in the viscosity characteristics of blood flow. It binds to platelets and contributes to their aggregation, promotes fibrin formation and is also an acute phase reactant that is increased in inflammatory states. Fibrinogen concentrations were measured in our laboratory by immuno-nephelometry (Siemens Healthcare Diagnostics, Deerfield IL, USA).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Interleukin 6 (IL-6) at 6 Months</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Value at 6 months minus value at baseline. IL-6 is a pro-inflammatory cytokine thought to produce a state of low-grade inflammation in obese individuals. IL-6 stimulates hepatic production of C-reactive protein (CRP), an acute phase protein which is a sensitive marker for systemic inflammation. IL-6 was measured by enzyme-linked immunosorbent assay (ELISA; R&amp;D Systems, Minneapolis, MN, USA).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Plasminogen Activator Inhibitor-1 (PAI-1) at 6 Months</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Value at 6 months minus value at baseline. PAI-1 is the primary physiological inhibitor of fibrinolysis and proteolysis. High PAI-1 levels have been linked to thrombosis and fibrosis, insulin resistance and obesity. PAI-1 was measured by ELISA (American Diagnostica, Stamford, CT, USA).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Diet/Exercise only, then Diet/Exercise plus Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diet/Exercise only in first intervention period and Diet/Exercise plus Metformin in second intervention period (no washout period).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diet/Exercise plus Metformin, then Diet/Exercise only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Diet/Exercise plus Metformin in first intervention period and Diet/Exercise only in second intervention period (no washout period).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin, 250mg by mouth twice a day with meals will be started and if tolerated increased to 500mg twice a day in 3 days in those less than 12 years old and titrated further to 1000mg twice a day if tolerated.</description>
    <arm_group_label>Diet/Exercise only, then Diet/Exercise plus Metformin</arm_group_label>
    <arm_group_label>Diet/Exercise plus Metformin, then Diet/Exercise only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Dietary modification with caloric restriction</intervention_name>
    <description>The life style intervention changes will include a hypocaloric diet representing at least a 500 kcal/day reduction based on their dietary histories and Resting Energy Expenditure (REE) determined by the initial calorimetry.</description>
    <arm_group_label>Diet/Exercise only, then Diet/Exercise plus Metformin</arm_group_label>
    <arm_group_label>Diet/Exercise plus Metformin, then Diet/Exercise only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Establishment of exercise protocol</intervention_name>
    <description>Participants will attend the Fitness Center 3 times per week and supervised by an exercise technician or exercise specialist. Exercise will be individually prescribed for each participant based on their functional abilities. Exercise will consist of 5-10 minutes for warm up and stretching, followed by 15-30 minutes of cardiovascular exercise (i.e. treadmill, bicycle ergometer, rower, nustep, etc), 10-20 minutes of strength training (supervised using weight stack equipment), and 5-10 minutes of cool down and stretching. As children typically do not need an exercise prescription based on heart rate, we will familiarize them with perceived exertion scales and monitor that they are exercising in the moderate to hard range of perception of effort. Participants will be started at 15 minutes of cardiovascular exercise and 10 minutes of strength training exercise, progressing by 2-3 minutes every week until 30 and 20 minutes is achieved for each respectively.</description>
    <arm_group_label>Diet/Exercise only, then Diet/Exercise plus Metformin</arm_group_label>
    <arm_group_label>Diet/Exercise plus Metformin, then Diet/Exercise only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages 7-18 years.

          -  Greater than the 95th percentile body mass index for their age and gender.

          -  Children are in Tanner Stage I or IV or V.

          -  Normal Blood Pressure.

          -  Normal fasting glucose.

          -  Normal lipids.

          -  Menstruating girls must have completed their most recent period at least 2 weeks prior
             to blood draw.

          -  No recent illness, no chronic illnesses, no routine medications, no smoking or alcohol
             intake.

          -  Must pass the screening test done in Protocol #1.

          -  Must have higher values than normal for certain blood tests related to heart disease
             that were measured in Protocol #1.

        Exclusion Criteria:

          -  Chronic active illnesses.

          -  Recent illnesses.

          -  Use of routine medications, vitamins, herbal remedies, oral contraceptive pills, or
             other over the counter medications within 4 weeks of blood draw.

          -  History of recent or chronic smoking.

          -  Currently pregnant.

          -  Impaired fasting glucose.

          -  Dyslipidemia.

          -  Actively in puberty.

          -  Weight greater than 300 pounds.

          -  Metal in the abdomen.

          -  History of being overweight greater than 5 years.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nelly Mauras, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nemours Children's Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nemours Children's Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Mauras N, Delgiorno C, Kollman C, Bird K, Morgan M, Sweeten S, Balagopal P, Damaso L. Obesity without established comorbidities of the metabolic syndrome is associated with a proinflammatory and prothrombotic state, even before the onset of puberty in children. J Clin Endocrinol Metab. 2010 Mar;95(3):1060-8. doi: 10.1210/jc.2009-1887. Epub 2010 Jan 8.</citation>
    <PMID>20061420</PMID>
  </results_reference>
  <results_reference>
    <citation>Rynders C, Weltman A, Delgiorno C, Balagopal P, Damaso L, Killen K, Mauras N. Lifestyle intervention improves fitness independent of metformin in obese adolescents. Med Sci Sports Exerc. 2012 May;44(5):786-92. doi: 10.1249/MSS.0b013e31823cef5e.</citation>
    <PMID>22015710</PMID>
  </results_reference>
  <results_reference>
    <citation>Mauras N, DelGiorno C, Hossain J, Bird K, Killen K, Merinbaum D, Weltman A, Damaso L, Balagopal P. Metformin use in children with obesity and normal glucose tolerance--effects on cardiovascular markers and intrahepatic fat. J Pediatr Endocrinol Metab. 2012;25(1-2):33-40.</citation>
    <PMID>22570948</PMID>
  </results_reference>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2005</study_first_submitted>
  <study_first_submitted_qc>August 30, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2005</study_first_posted>
  <results_first_submitted>June 25, 2012</results_first_submitted>
  <results_first_submitted_qc>September 9, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 11, 2012</results_first_posted>
  <last_update_submitted>October 21, 2012</last_update_submitted>
  <last_update_submitted_qc>October 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nemours Children's Clinic</investigator_affiliation>
    <investigator_full_name>Nelly Mauras</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants recruited from pediatric endocrinology clinics, in Jacksonville, USA between November 2003 and April 2008.</recruitment_details>
      <pre_assignment_details>375 participants recruited; 177 obese participants screened, 111 excluded (62 did not meet inclusion criteria and 4 refused participation).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Diet/Exercise Only, Then Diet/Exercise Plus Metformin</title>
          <description>Diet/Exercise only in first intervention period and Diet/Exercise plus Metformin in second intervention period (no washout period).</description>
        </group>
        <group group_id="P2">
          <title>Diet/Exercise Plus Metformin, Then Diet/Exercise Only</title>
          <description>Diet/Exercise plus Metformin in first intervention period and Diet/Exercise only in second intervention period (no washout period).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention -Baseline to 6Months</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>No Longer Interested</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Relocation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Impaired Glucose Tolerance at Screening</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention -6Months to 12Months</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>No Longer Interested</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Relocation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Diet/Exercise Only, Then Diet/Exercise Plus Metformin</title>
          <description>Diet/Exercise only in first intervention period and Diet/Exercise plus Metformin in second intervention period (no washout period).</description>
        </group>
        <group group_id="B2">
          <title>Diet/Exercise Plus Metformin, Then Diet/Exercise Only</title>
          <description>Diet/Exercise plus Metformin in first intervention period and Diet/Exercise only in second intervention period (no washout period).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
            <count group_id="B2" value="35"/>
            <count group_id="B3" value="66"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12" spread="0.4"/>
                    <measurement group_id="B2" value="12.3" spread="0.5"/>
                    <measurement group_id="B3" value="12.2" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Protocol #1: Serum Marker Levels Between Obese and Lean Children</title>
        <description>This outcome measure is from Protocol #1 (a cross-sectional study); results are not posted.</description>
        <time_frame>Screening Visit</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in High-sensitivity C-reactive Protein (hsCRP) at 6 Months</title>
        <description>Value at 6 months minus value at baseline. HsCRP is an acute phase protein which is a sensitive marker for systemic inflammation. HsCRP concentrations were measured in our laboratory by immuno-nephelometry (Siemens Healthcare Diagnostics, Deerfield IL, USA), with an hsCRP lower sensitivity of 0.156 mg/L.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <population>1 Subject in the &quot;Diet/Exercise plus Metformin, then Diet/Exercise (Pubertal)&quot; Group did not have an hsCRP level available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Diet/Exercise, Then Diet/Exercise Plus Metformin (Prepubertal)</title>
            <description>Diet/Exercise only in first intervention period and Diet/Exercise plus Metformin in second intervention period (no washout period). Results displayed for prepubertal versus pubertal participants.</description>
          </group>
          <group group_id="O2">
            <title>Diet/Exercise, Then Diet/Exercise Plus Metformin (Pubertal)</title>
            <description>Diet/Exercise only in first intervention period and Diet/Exercise plus Metformin in second intervention period (no washout period). Results displayed for prepubertal versus pubertal participants.</description>
          </group>
          <group group_id="O3">
            <title>Diet/Exercise Plus Metformin, Then Diet/Exercise (Prepubertal)</title>
            <description>Diet/Exercise plus Metformin in first intervention period and Diet/Exercise only in second intervention period (no washout period). Results displayed for prepubertal versus pubertal participants.</description>
          </group>
          <group group_id="O4">
            <title>Diet/Exercise Plus Metformin, Then Diet/Exercise (Pubertal)</title>
            <description>Diet/Exercise plus Metformin in first intervention period and Diet/Exercise only in second intervention period (no washout period). Results displayed for prepubertal versus pubertal participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in High-sensitivity C-reactive Protein (hsCRP) at 6 Months</title>
          <description>Value at 6 months minus value at baseline. HsCRP is an acute phase protein which is a sensitive marker for systemic inflammation. HsCRP concentrations were measured in our laboratory by immuno-nephelometry (Siemens Healthcare Diagnostics, Deerfield IL, USA), with an hsCRP lower sensitivity of 0.156 mg/L.</description>
          <population>1 Subject in the &quot;Diet/Exercise plus Metformin, then Diet/Exercise (Pubertal)&quot; Group did not have an hsCRP level available for analysis.</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.37" lower_limit="-1.54" upper_limit="0.81"/>
                    <measurement group_id="O2" value="-1.78" lower_limit="-5.49" upper_limit="-0.15"/>
                    <measurement group_id="O3" value="-0.29" lower_limit="-1.42" upper_limit="1.79"/>
                    <measurement group_id="O4" value="0.00" lower_limit="-0.65" upper_limit="2.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Fibrinogen at 6 Months</title>
        <description>Value at 6 months minus value at baseline. Fibrinogen is a hepatic-derived factor directly involved in clotting and in the viscosity characteristics of blood flow. It binds to platelets and contributes to their aggregation, promotes fibrin formation and is also an acute phase reactant that is increased in inflammatory states. Fibrinogen concentrations were measured in our laboratory by immuno-nephelometry (Siemens Healthcare Diagnostics, Deerfield IL, USA).</description>
        <time_frame>Baseline and 6 months</time_frame>
        <population>1 Subject in the &quot;Diet/Exercise plus Metformin, then Diet/Exercise (Pubertal)&quot; Group did not have a Fibrinogen level available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Diet/Exercise, Then Diet/Exercise Plus Metformin (Prepubertal)</title>
            <description>Diet/Exercise only in first intervention period and Diet/Exercise plus Metformin in second intervention period (no washout period). Results displayed for prepubertal versus pubertal participants.</description>
          </group>
          <group group_id="O2">
            <title>Diet/Exercise, Then Diet/Exercise Plus Metformin (Pubertal)</title>
            <description>Diet/Exercise only in first intervention period and Diet/Exercise plus Metformin in second intervention period (no washout period). Results displayed for prepubertal versus pubertal participants.</description>
          </group>
          <group group_id="O3">
            <title>Diet/Exercise Plus Metformin, Then Diet/Exercise (Prepubertal)</title>
            <description>Diet/Exercise plus Metformin in first intervention period and Diet/Exercise only in second intervention period (no washout period). Results displayed for prepubertal versus pubertal participants.</description>
          </group>
          <group group_id="O4">
            <title>Diet/Exercise Plus Metformin, Then Diet/Exercise (Pubertal)</title>
            <description>Diet/Exercise plus Metformin in first intervention period and Diet/Exercise only in second intervention period (no washout period). Results displayed for prepubertal versus pubertal participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fibrinogen at 6 Months</title>
          <description>Value at 6 months minus value at baseline. Fibrinogen is a hepatic-derived factor directly involved in clotting and in the viscosity characteristics of blood flow. It binds to platelets and contributes to their aggregation, promotes fibrin formation and is also an acute phase reactant that is increased in inflammatory states. Fibrinogen concentrations were measured in our laboratory by immuno-nephelometry (Siemens Healthcare Diagnostics, Deerfield IL, USA).</description>
          <population>1 Subject in the &quot;Diet/Exercise plus Metformin, then Diet/Exercise (Pubertal)&quot; Group did not have a Fibrinogen level available for analysis.</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.5" lower_limit="-64" upper_limit="123.75"/>
                    <measurement group_id="O2" value="-105" lower_limit="-141" upper_limit="-31"/>
                    <measurement group_id="O3" value="0.00" lower_limit="-51.5" upper_limit="83"/>
                    <measurement group_id="O4" value="-33" lower_limit="-93.5" upper_limit="40.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Interleukin 6 (IL-6) at 6 Months</title>
        <description>Value at 6 months minus value at baseline. IL-6 is a pro-inflammatory cytokine thought to produce a state of low-grade inflammation in obese individuals. IL-6 stimulates hepatic production of C-reactive protein (CRP), an acute phase protein which is a sensitive marker for systemic inflammation. IL-6 was measured by enzyme-linked immunosorbent assay (ELISA; R&amp;D Systems, Minneapolis, MN, USA).</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diet/Exercise, Then Diet/Exercise Plus Metformin (Prepubertal)</title>
            <description>Diet/Exercise only in first intervention period and Diet/Exercise plus Metformin in second intervention period (no washout period). Results displayed for prepubertal versus pubertal participants.</description>
          </group>
          <group group_id="O2">
            <title>Diet/Exercise, Then Diet/Exercise Plus Metformin (Pubertal)</title>
            <description>Diet/Exercise only in first intervention period and Diet/Exercise plus Metformin in second intervention period (no washout period). Results displayed for prepubertal versus pubertal participants.</description>
          </group>
          <group group_id="O3">
            <title>Diet/Exercise Plus Metformin, Then Diet/Exercise (Prepubertal)</title>
            <description>Diet/Exercise plus Metformin in first intervention period and Diet/Exercise only in second intervention period (no washout period). Results displayed for prepubertal versus pubertal participants.</description>
          </group>
          <group group_id="O4">
            <title>Diet/Exercise Plus Metformin, Then Diet/Exercise (Pubertal)</title>
            <description>Diet/Exercise plus Metformin in first intervention period and Diet/Exercise only in second intervention period (no washout period). Results displayed for prepubertal versus pubertal participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Interleukin 6 (IL-6) at 6 Months</title>
          <description>Value at 6 months minus value at baseline. IL-6 is a pro-inflammatory cytokine thought to produce a state of low-grade inflammation in obese individuals. IL-6 stimulates hepatic production of C-reactive protein (CRP), an acute phase protein which is a sensitive marker for systemic inflammation. IL-6 was measured by enzyme-linked immunosorbent assay (ELISA; R&amp;D Systems, Minneapolis, MN, USA).</description>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.66" lower_limit="-2.39" upper_limit="-0.01"/>
                    <measurement group_id="O2" value="-0.99" lower_limit="-2.11" upper_limit="0.22"/>
                    <measurement group_id="O3" value="0.2" lower_limit="-0.80" upper_limit="2.19"/>
                    <measurement group_id="O4" value="-0.35" lower_limit="-0.94" upper_limit="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Plasminogen Activator Inhibitor-1 (PAI-1) at 6 Months</title>
        <description>Value at 6 months minus value at baseline. PAI-1 is the primary physiological inhibitor of fibrinolysis and proteolysis. High PAI-1 levels have been linked to thrombosis and fibrosis, insulin resistance and obesity. PAI-1 was measured by ELISA (American Diagnostica, Stamford, CT, USA).</description>
        <time_frame>Baseline and 6 months</time_frame>
        <population>1 Subject in the &quot;Diet/Exercise plus Metformin, then Diet/Exercise (Pubertal)&quot; Group and 1 Subject in the &quot;Diet/Exercise, then Diet/Exercise plus Metformin (Pubertal)&quot; Group did not have a PAI-1 level available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Diet/Exercise, Then Diet/Exercise Plus Metformin (Prepubertal)</title>
            <description>Diet/Exercise only in first intervention period and Diet/Exercise plus Metformin in second intervention period (no washout period). Results displayed for prepubertal versus pubertal participants.</description>
          </group>
          <group group_id="O2">
            <title>Diet/Exercise, Then Diet/Exercise Plus Metformin (Pubertal)</title>
            <description>Diet/Exercise only in first intervention period and Diet/Exercise plus Metformin in second intervention period (no washout period). Results displayed for prepubertal versus pubertal participants.</description>
          </group>
          <group group_id="O3">
            <title>Diet/Exercise Plus Metformin, Then Diet/Exercise (Prepubertal)</title>
            <description>Diet/Exercise plus Metformin in first intervention period and Diet/Exercise only in second intervention period (no washout period). Results displayed for prepubertal versus pubertal participants.</description>
          </group>
          <group group_id="O4">
            <title>Diet/Exercise Plus Metformin, Then Diet/Exercise (Pubertal)</title>
            <description>Diet/Exercise plus Metformin in first intervention period and Diet/Exercise only in second intervention period (no washout period). Results displayed for prepubertal versus pubertal participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasminogen Activator Inhibitor-1 (PAI-1) at 6 Months</title>
          <description>Value at 6 months minus value at baseline. PAI-1 is the primary physiological inhibitor of fibrinolysis and proteolysis. High PAI-1 levels have been linked to thrombosis and fibrosis, insulin resistance and obesity. PAI-1 was measured by ELISA (American Diagnostica, Stamford, CT, USA).</description>
          <population>1 Subject in the &quot;Diet/Exercise plus Metformin, then Diet/Exercise (Pubertal)&quot; Group and 1 Subject in the &quot;Diet/Exercise, then Diet/Exercise plus Metformin (Pubertal)&quot; Group did not have a PAI-1 level available for analysis.</population>
          <units>ng/ML</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.98" lower_limit="-48.54" upper_limit="14.4"/>
                    <measurement group_id="O2" value="-46.84" lower_limit="-62.86" upper_limit="-24.46"/>
                    <measurement group_id="O3" value="0.55" lower_limit="-34.45" upper_limit="34.22"/>
                    <measurement group_id="O4" value="-34.42" lower_limit="-46.74" upper_limit="25.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Diet/Exercise Only, Then Diet/Exercise Plus Metformin</title>
          <description>Diet/Exercise only in first intervention period and Diet/Exercise plus Metformin in second intervention period (no washout period).</description>
        </group>
        <group group_id="E2">
          <title>Diet/Exercise Plus Metformin, Then Diet/Exercise Only</title>
          <description>Diet/Exercise plus Metformin in first intervention period and Diet/Exercise only in second intervention period (no washout period).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Protocol #2 attrition was high, such that, we could not derive conclusions beyond the 6 month time period. Therefore, conclusions were based on participants after completing the first intervention without crossover to the second intervention.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Nelly Mauras, Chief, Division of Endocrinology</name_or_title>
      <organization>Nemours Children's Clinic</organization>
      <phone>904-697-3674</phone>
      <email>nmauras@nemours.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

